Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly FCF Margin of 779.81% for Q1 2026, up 11639.0% year-over-year from N/an in Q1 2025, and down 158.59% quarter-over-quarter from 301.56% in Q4 2025.
Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported FCF Margin for 12 consecutive years, with 779.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 11639.0% year-over-year to 779.81%; the TTM figure through Mar 2026 stood at 551.05% (up 27254.0% YoY), while the FY2025 annual figure was 584.98%, up 1881.0% from the prior year.
- FCF Margin slipped to 779.81% in Q1 2026 per NTLA's latest filing, from 301.56% in the prior quarter.
- Across five years, FCF Margin topped out at 4283.46% in Q4 2023 and bottomed at 928.33% in Q3 2024.
- Historically, FCF Margin has averaged 402.77% across 5 years, with a median of 698.33% in 2023.
- Annual changes were most pronounced in 2023 — FCF Margin soared 494148 bps — and 2024, when it slumped 494680 bps.
- Intellia Therapeutics' FCF Margin stood at 658.01% in 2022, then soared by 751 bps to 4283.46% in 2023, then slumped by 115 bps to 663.34% in 2024, then surged by 55 bps to 301.56% in 2025, then slumped by 159 bps to 779.81% in 2026.
- Business Quant data shows NTLA's FCF Margin at 779.81% in Q1 2026, 301.56% in Q4 2025, and 565.24% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -1,108.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,108.79% |
| Mar 31, 2026 | -779.81% |
| Dec 31, 2025 | -301.56% |
| Sep 30, 2025 | -565.24% |
| Jun 30, 2025 | -698.77% |
| Mar 31, 2025 | -896.20% |
| Dec 31, 2024 | -663.34% |
| Sep 30, 2024 | -928.33% |
| Jun 30, 2024 | -809.41% |
| Mar 31, 2024 | -425.67% |
| Dec 31, 2023 | 4,283.46% |
| Sep 30, 2023 | -881.53% |
| Jun 30, 2023 | -698.33% |
| Mar 31, 2023 | -895.23% |
| Dec 31, 2022 | -658.01% |
| Sep 30, 2022 | -580.10% |
| Jun 30, 2022 | -606.70% |
| Mar 31, 2022 | -742.29% |
| Dec 31, 2021 | -447.48% |
| Sep 30, 2021 | -965.57% |